Kyverna Therapeutics, Inc. Common Stock (KYTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $300.94M
Last updated: Nov 17, 2026 at 4:15 PM ET
Kyverna Therapeutics, Inc. Common Stock (KYTX) Statistics
Kyverna Therapeutics, Inc. Common Stock (KYTX) has a market cap of $300.94M and an enterprise value of $294.08M. Its share count is up 42.71% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 2.28% below the market cap, as cash exceeds debt.
| Market Cap | $300.94M |
|---|---|
| Enterprise Value | $294.08M |
| Latest price (Nov 17, 2026) | $4.70 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 31.69% over 52 weeks and trades 22.70% below its 50-day average.
| Beta (1Y) | 2.25 |
|---|---|
| 52-Week Change | -31.69% |
| 1-Month Change | -19.38% |
| 3-Month Change | -47.01% |
| 6-Month Change | -45.98% |
| Total Return (1Y) | -31.69% |
| Return vs SPY (1Y) | -51.53% |
| Max Drawdown (1Y) | -59.02% |
| Max Drawdown (3Y) | -93.92% |
| Sharpe Ratio (1Y) | -0.58 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $6.08 |
| 200-Day Average | $7.85 |
| 52-Week Range | $4.50 to $13.67 |
| RSI (14 Days) | 33.9 |
| Average Volume (20 Days) | 822.20K |
Financial Position
Current assets cover 7.01x current liabilities, and total debt is 0.19x shareholder equity.
| Current Ratio | 7.01x |
|---|---|
| Quick Ratio | 7.01x |
| Debt / Equity | 0.19x |
| Interest Coverage | -64.94x |
Returns and Efficiency
Return on invested capital is -81.50% and return on equity is -118.50% over the last 12 months.
| Return on Equity (ROE) | -118.50% |
|---|---|
| Return on Assets (ROA) | -83.30% |
| Return on Invested Capital (ROIC) | -81.50% |
| ROA (5Y Average) | -50.20% |
Scores
KYTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$368.00K |
| Operating Income | -$163.10M |
| Pretax Income | -$157.79M |
| Net Income | -$157.79M |
| Reported EPS (TTM) | -$2.77 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 70.29% of the $189.44M in total assets.
| Cash and Equivalents | $31.82M |
|---|---|
| Total Debt | $24.96M |
| Net Cash | $6.86M |
| Net Cash Per Share | $0.11 |
| Working Capital | $151.12M |
| Shareholder Equity | $133.15M |
| Book Value Per Share | $2.15 |
| Total Assets | $189.44M |
| Total Liabilities | $56.28M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.61M of capital spending, operating cash flow left -$152.41M of free cash flow.
| Operating Cash Flow | -$150.80M |
|---|---|
| Capital Expenditures | $1.61M |
| Free Cash Flow | -$152.41M |
| FCF Per Share | -$2.46 |
| Depreciation and Amortization | $3.91M |
| Share Repurchases | $359.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
KYTX does not pay a dividend. Its free cash flow yield is -52.34%.
| FCF Yield | -52.34% |
|---|---|
| Buyback Yield | -42.76% |
| Shareholder Yield | -42.76% |
Peer Position
Against 3 similar companies, KYTX has the lowest ROIC.
ROICPeer median -32.76%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -76.37%
| ROIC | -81.50% vs -32.76% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -76.37% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KYTX
What is KYTX's market cap?
Kyverna Therapeutics, Inc. Common Stock has a market cap of $300.94M. Its enterprise value, which adds debt and subtracts cash, is $294.08M.
How many shares of KYTX are outstanding?
Kyverna Therapeutics, Inc. Common Stock has 61.96M shares outstanding. The count is up 42.71% from a year earlier.
Does KYTX pay a dividend?
No. Kyverna Therapeutics, Inc. Common Stock does not pay a dividend.
How much debt does KYTX have?
Kyverna Therapeutics, Inc. Common Stock has $24.96M of total debt and $31.82M of cash and equivalents, a net cash position of $6.86M.
KYTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors